Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 137 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Conversion Disorder Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy Long-term Dietary Nitrate Consumption to Plasma Nitrite Conversion

NCT05380167
View directory record Official record
Conditions
Cardiovascular Diseases in Old Age
Interventions
BRJ Nitrate, BRJ Placebo
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
40 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 1, 2026, 2:27 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effective Conversion of Individuals at Risk

NCT05112757
View directory record Official record
Conditions
Obstructive Sleep Apnea, Atrial Fibrillation
Interventions
Smartphone application use
Other
Lead sponsor
Philips Electronics Nederland B.V. acting through Philips CTO organization
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 1, 2026, 2:27 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

NCT03464019
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil, Placebo, Etripamil Test Dose
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 1, 2026, 2:27 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Neuroimaging Biomarker for Seizures

NCT03441867
View directory record Official record
Conditions
Seizure Disorder, Seizure Disorder, Post Traumatic, Traumatic Brain Injury, Non-Epileptic Seizure, Conversion Disorder, Magnetic Resonance Imaging, Head Injury, Epilepsy
Interventions
Cognitive Behavioral Therapy for Seizures, Standard Medical Care
Behavioral · Other
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
3
States / cities
Birmingham, Alabama • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 1, 2026, 2:27 PM EDT
Completed No phase listed Observational

Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD)

NCT04565080
View directory record Official record
Conditions
Parkinson's Disease, Functional Movement Disorders, COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Sep 1, 2026, 2:27 PM EDT
Completed Phase 3 Interventional

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects

NCT00126061
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Tedisamil sesquifumarate
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Los Angeles, California • Santa Ana, California • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 1, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain

NCT00312572
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 85 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 1, 2026, 2:27 PM EDT
Completed No phase listed Observational

Gastric Bypass After Previous Anti-reflux Surgery

NCT01041105
View directory record Official record
Conditions
Clinically Severe Obesity, Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2009 · Synced Sep 1, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy

NCT00355082
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
lamotrigine, 300 mg/day, lamotrigine, 250 mg/day
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
67
States / cities
Alabaster, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 1, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

NCT00817206
View directory record Official record
Conditions
Renal Failure
Interventions
LCP-Tacro, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Sep 1, 2026, 2:27 PM EDT
Completed Early Phase 1 Interventional

Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures

NCT00500994
View directory record Official record
Conditions
Movement Disorders
Interventions
MRI
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
2
States / cities
Bethesda, Maryland • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 1, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants

NCT04124705
View directory record Official record
Conditions
Hypothyroidism, Thyroid Disease, Euthyroid, Thyroid Gland, Thyroid Hormones
Interventions
Armour® Thyroid, Levothyroxine
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Greenbrae, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 1, 2026, 2:27 PM EDT
Recruiting Phase 2Phase 3 Interventional

CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients

NCT03769298
View directory record Official record
Conditions
Kidney Pancreas Transplantation
Interventions
Envarsus XR
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 1, 2026, 2:27 PM EDT
Recruiting Not applicable Interventional

Cognitive Rehabilitation for Veterans With PNES

NCT07316543
View directory record Official record
Conditions
Psychogenic Nonepileptic Seizures (PNES)
Interventions
Cognitive Rehabilitation And Functional Treatment (CRAFT)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 1, 2026, 2:27 PM EDT
Recruiting Early Phase 1 Interventional

Accelerated TMS for Seizure-Type Functional Neurologic Disorders

NCT07059325
View directory record Official record
Conditions
Functional Neurological Symptom Disorder, Functional Seizures
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 1, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

NCT04623086
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin Degludec, Insulin Glargine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 1, 2026, 2:27 PM EDT
Withdrawn Not applicable Interventional

Demonstrating Efficacy of JOGO for the Treatment of Tremor

NCT06346873
View directory record Official record
Conditions
Functional Neurological Disorder
Interventions
JOGO
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 1, 2026, 2:27 PM EDT
Not yet recruiting Not applicable Interventional

Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort

NCT06078527
View directory record Official record
Conditions
Presbylarynx, Aspiration, Spasmodic Dysphonia, Globus Pharyngeus, Larynx Paralysis, Laryngeal Disease, Vocal Cord Paralysis, Iatrogenic Injury, Sensory Neuropathy
Interventions
Cheung-Bearelly Aesthesiometer, Transnasal Laryngoscopy, Questionnaires
Device · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 1, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction

NCT01935128
View directory record Official record
Conditions
Renal Transplant
Interventions
Arm 1 Everolimus/Reduced dose tacrolimus
Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 1, 2026, 2:27 PM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

NCT05082571
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
4 Months to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 1, 2026, 2:27 PM EDT
Completed Phase 1Phase 2 Interventional

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

NCT02302989
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Leonard Feiner, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Teaneck, New Jersey • Vauxhall, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 1, 2026, 2:27 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)

NCT02256085
View directory record Official record
Conditions
Depersonalization Disorder
Interventions
Daily rTMS with Active coil, Daily rTMS with Sham coil, Open Label Daily rTMS with Active coil
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 1, 2026, 2:27 PM EDT
Completed Phase 3 Interventional

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects

NCT00126074
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Tedisamil sesquifumarate
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Honolulu, Hawaii • Tullahoma, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 1, 2026, 2:27 PM EDT
Not listed Phase 4 Interventional

Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote

NCT00312676
View directory record Official record
Conditions
Epilepsy, Behavioral Disturbance
Interventions
Rapid versus slow conversion
Procedure
Lead sponsor
Veterans Affairs Medical Center, Miami
Federal
Eligibility
60 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2006 · Synced Sep 1, 2026, 2:27 PM EDT